Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2782 - Overall Survival and Immunologic Responses in Metastatic Pancreatic Adenocarcinoma (PDAC) on PEGylated Human IL-10 (AM0010) with 5-FU/LV and Oxaliplatin (FOLFOX)

Date

09 Sep 2017

Session

Poster display session

Presenters

J. Randy Hecht

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

J..R. Hecht1, A. Naing2, G. Falchook3, M.R. Patel4, J.R. Infante5, R. Aljumaily6, D.J. Wong7, K. Autio8, Z.A. Wainberg1, M. Javle2, J.C. Bendell9, S. Pant10, A. Hung11, P. Van Vlasselaer11, G. Brown11, M. Oft11, K. Papadopoulos12

Author affiliations

  • 1 Medicine, UCLA, 90095 - Los Angeles/US
  • 2 Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Healthone, Sarah Cannon Research Institute, Denver/US
  • 4 Oncology, Sarah Cannon Research Institute (Nashville, TN); Florida Cancer Specialists & Research Institute, Sarasota/US
  • 5 Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, 37203 - Nashville/US
  • 6 Hematology/oncology, Oklahoma University Medical Centre, Oklahoma City/US
  • 7 Department Of Medicine, University of California, Los Angeles, 90024 - Los Angeles/US
  • 8 Genitourinary Oncology, MSKCC, 10065 - New York/US
  • 9 Medical Oncology, Sarah Cannon Research Institute and Tennessee Oncology, 37203 - Nashville/US
  • 10 Oncology, College of Pharmacy, OUHSC, 73117 - Oklahoma City/US
  • 11 Clinical Development, ARMO BioSciences, 94063 - Redwood City/US
  • 12 Oncology, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
More

Resources

Abstract 2782

Background

Median overall survival on 2nd line therapy of PDAC with 5-FU/LV plus oxaliplatin or nal-irinotecan is ∼ 5-6 m. PDAC is refractory to immune therapies and mutational burden is relatively low and tumor infiltrating CD8+ T cells are rare. AM0010 stimulates survival, expansion and cytotoxicity of intratumoral CD8+ T cells and induced immune activation, durable stable disease and a 1yr survival of 22.5% in salvage PDAC pts. AM0010 has synergistic immune and anti-tumor activity with platinums and 5-FU in preclinical cancer models.

Methods

This phase 1b clinical study studied the safety and efficacy of AM0010 +FOLFOX as ≥ 2nd line treatment of PDAC. Pts who progressed on a median of 2 prior therapies (range 1-3) were treated with AM0010 (5ug/kg SQ, qd) + FOLFOX (n = 21). The safety population (n = 25) included four additional pts with prior FOLFOX. Tumor responses were assessed using irRC. Serum cytokines, activation of blood derived T cells and peripheral T cell clonality were analyzed. Pre-existing tumor infiltrating CD8 T cells were quantified by IHC.

Results

AM0010 + FOLFOX was generally well tolerated. G3/4 TrAEs included thrombocytopenia (52%), anemia (40%) and neutropenia (36%). Most cytopenias were transient and met retreatment criteria within 2-5 days. A modified AM0010 dose schedule of 5 days on, 2 days off avoided G3/4 cytopenias while retaining the immune stimulation. As of 05/1/2017, 2 pts have remained on treatment for > 72 weeks. 19 pts had tumor assessment following irRC (2 CR, 1 PR, 11 SD). The ORR and DCR were 15.8% and 74%. With a median follow-up of 14.2 m (range 6.8-18.9), 10 patients were alive (48%), mPFS and mOS were 3.5 and 10.2 m. Treatment induced a sustained cytokine increase in the serum and an expansion of novel T cell clones in the blood. This and a higher number of intra-tumoral CD8 T cells correlated with increased OS.

Conclusions

The combination of AM0010 with FOLFOX is well tolerated in patients with metastatic PDAC. This regimen induced sustained immune activation including the expansion of oligoclonal T cells. The prolonged tumor responses and OS are encouraging in this advanced population. This regimen is being studied in a phase 3 trial.

Clinical trial identification

NCT02009449

Legal entity responsible for the study

Armo BioSciences

Funding

ARMO BioSciences

Disclosure

A. Hung, G. Brown: Employee of ARMO BioSciences. P. Van Vlasselaer: Stock, leadership, employee of ARMO BioSciences. M. Oft: Employee of ARMO BioSciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings